TQB3820
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 21, 2021
TQB3820-I-01: A Study of TQB3820 in Patients With Hematological Malignancies
(clinicaltrials.gov)
- P1; N=116; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology
August 25, 2021
TQB3820-I-01: A Study of TQB3820 in Patients With Hematological Malignancies
(clinicaltrials.gov)
- P1; N=116; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical • New P1 trial • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology
1 to 2
Of
2
Go to page
1